Does aprotinin increase the long-term risk of mortality in patients undergoing CABG surgery?
Ken Taylor
Correspondence British Heart Foundation Department of Cardiac Surgery, National Heart and Lung Institute, Imperial College, Hammersmith Hospital, B Block, Second Floor, Du Cane Road, London W12 0HS, UK
Email k.m.taylor@ic.ac.uk
This article has no abstract so we have provided the first paragraph of the full text.
Twenty years have passed since we first reported in a randomized, placebo-controlled, prospective study the substantial hemostatic benefits of high-dose aprotinin (Hammersmith regimen: loading dose = 2 million KIU; cardiopulmonary bypass pump prime dose = 2 million KIU; dose during bypass = 0.5 million KIU/h) in patients undergoing repeat cardiac surgery and those at high risk of excessive bleeding.1 The intervening years have seen widespread adoption of this therapy, with numerous randomized trials confirming its efficacy and safety.2
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Tissue sealants: Current status, future potentialNature Medicine News and Views (01 Jun 1996)
